Royal Bank Of Canada Cuts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $128.00

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price objective decreased by equities researchers at Royal Bank Of Canada from $130.00 to $128.00 in a research note issued on Thursday, Marketbeat.com reports. The brokerage presently has an “outperform” rating on the stock. Royal Bank Of Canada’s price target suggests a potential upside of 36.23% from the company’s previous close.

A number of other analysts also recently commented on the stock. HC Wainwright boosted their price target on shares of Mirum Pharmaceuticals from $102.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Citigroup restated an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Friday, December 19th. Robert W. Baird lifted their price target on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. Raymond James Financial reissued a “strong-buy” rating and issued a $110.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday, December 11th. Finally, Leerink Partners set a $100.00 target price on Mirum Pharmaceuticals in a research note on Wednesday, December 10th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Mirum Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $111.58.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM traded down $14.66 during midday trading on Thursday, hitting $93.96. 733,883 shares of the stock traded hands, compared to its average volume of 755,419. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31. Mirum Pharmaceuticals has a 1-year low of $36.88 and a 1-year high of $109.28. The business’s 50 day moving average price is $92.67 and its two-hundred day moving average price is $78.81. The firm has a market capitalization of $4.83 billion, a PE ratio of -109.55 and a beta of 0.49.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Wednesday, February 25th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.13). The business had revenue of $148.93 million during the quarter, compared to analyst estimates of $141.78 million. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The firm’s revenue was up 49.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.00 earnings per share. Equities research analysts predict that Mirum Pharmaceuticals will post -1.43 EPS for the current fiscal year.

Insider Transactions at Mirum Pharmaceuticals

In related news, CEO Christopher Peetz sold 9,108 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $103.30, for a total value of $940,856.40. Following the completion of the transaction, the chief executive officer directly owned 160,294 shares in the company, valued at approximately $16,558,370.20. The trade was a 5.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Joanne Quan sold 6,911 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $90.27, for a total value of $623,855.97. Following the sale, the insider owned 11,305 shares in the company, valued at $1,020,502.35. The trade was a 37.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 45,136 shares of company stock worth $4,352,029. 14.36% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in MIRM. Cullen Frost Bankers Inc. purchased a new stake in Mirum Pharmaceuticals during the 4th quarter valued at about $30,000. MCF Advisors LLC boosted its stake in Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after acquiring an additional 185 shares in the last quarter. Eurizon Capital SGR S.p.A. bought a new position in shares of Mirum Pharmaceuticals during the fourth quarter valued at $32,000. CIBC Private Wealth Group LLC purchased a new position in Mirum Pharmaceuticals in the fourth quarter worth about $32,000. Finally, Quantbot Technologies LP bought a new stake in shares of Mirum Pharmaceuticals during the third quarter valued at approximately $33,000.

Mirum Pharmaceuticals News Summary

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Revenue beat and strong top-line growth: Q4 revenue was $148.93M vs. consensus $141.78M, up ~49.8% year-over-year — evidence of accelerating commercial traction. Business Wire: Q4 Results
• Neutral Sentiment: Earnings call details available — management provided a business update and commentary on execution and the outlook; read the call transcript for color on commercial drivers and any pipeline or margin comments. Fool: Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Market momentum and technicals are under discussion — sentiment pieces note strong upward momentum over the past year but warn technical indicators are stretched, which could amplify near-term volatility. Seeking Alpha: Technicals Article
• Negative Sentiment: EPS miss and ongoing GAAP loss: Q4 EPS of ($0.11) missed consensus $0.02, and the company remains unprofitable (negative net margin and ROE), which keeps profitability risk front-and-center for investors. Zacks: Q4 Loss, Revenue Beat
• Negative Sentiment: FY2026 revenue guidance of $630M–$650M is slightly below consensus (~$645.9M) and EPS guidance was not clearly raised in the release, leaving uncertainty on near-term profitability improvement. Business Wire: Guidance

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.